Mobile

A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-000983-27

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.

Critère d'inclusion

  • Mild and moderate hepatic impairment

Liens